Immunotherapy
Conference Coverage
CAR T-cell benefit in lenalidomide-refractory myeloma
“Early CAR Ts demonstrating efficacy and safety and prior lines of treatment impact survival from CAR T in myeloma. Can this also be true for...
Latest News
Warts difficult to eradicate in immunocompromised children
Warts completely resolved with treatment in only 24% of children undergoing active cancer treatment.
Conference Coverage
Antibody-drug conjugate changes standard of care for platinum-resistant ovarian cancer
A novel therapy has a favorable safety profile, and more like it may be on the way.
Conference Coverage
Up-front pembro plus chemo boost survival in cervical cancer
Adding immunotherapy resulted in a 40% reduction in risk of death, compared with chemotherapy alone, for women with advanced cervical cancers...
Conference Coverage
‘Huge step forward’ in advanced ovarian cancer
A preplanned interim analysis revealed that the addition of durvalumab and olaparib was associated with a 37% improvement of PFS, compared with...
Conference Coverage
SCLC: Bispecific antibody shows phase 1 promise
The antibody targets delta-like ligand 3, which is one of few surface markers for small cell lung cancer.
Conference Coverage
‘Exciting’ results for cancer vaccine plus pembro in melanoma
A new randomized study is the first to demonstrate improvement in recurrence-free survival in melanoma with an individualized neoantigen vaccine...
Conference Coverage
Durvalumab pre, post surgery in NSCLC: Practice changing?
A new study’s findings confirm the benefits of neoadjuvant immunotherapy.
Conference Coverage
Study gives new insight into timing of combo treatment in metastatic NSCLC
Best outcomes came when immunotherapy followed radiotherapy by 1-12 months.
From the Journals
Thoracic cancer approvals differ at FDA, EMA
The EMA had fewer approvals and took longer to make decisions.
Conference Coverage
In metastatic NSCLC, better QoL outcomes tied to better outcomes
But the authors of new research also found potential evidence that industry sponsorship may lead to a spin on QoL outcomes.